KingMylab has supported over 500 clinical projects related to solid tumor research. Our depth of experience and quality of service, as well as our long-term collaborations with leading national and multi-national pharmaceuticals, has helped bring to market many novel Class I therapies in China. We aim to constantly improve our central laboratory capabilities to accelerate the development of innovative drugs in the ongoing fight against cancer.

KingMylab has supported over 500 clinical projects related to solid tumor research. Our depth of experience and quality of service, as well as our long-term collaborations with leading national and multi-national pharmaceuticals, has helped bring to market many novel Class I therapies in China. We aim to constantly improve our central laboratory capabilities to accelerate the development of innovative drugs in the ongoing fight against cancer.

KingMylab has supported over 500 clinical projects related to solid tumor research. Our depth of experience and quality of service, as well as our long-term collaborations with leading national and multi-national pharmaceuticals, has helped bring to market many novel Class I therapies in China. We aim to constantly improve our central laboratory capabilities to accelerate the development of innovative drugs in the ongoing fight against cancer.

KingMylab has accumulated more than 500 clinical trial projects in the field of solid tumor research, with rich professional project execution experience. It has cooperated with many well-known pharmaceutical companies and carried out central laboratory services covering dozens of common tumors in China. It has helped many Class 1 anti-tumor innovative drugs in China to be successfully launched. It is committed to providing the best laboratory practice for tumor clinical trials and enabling the development of new tumor drugs.